Deutsche Bank Aktiengesellschaft Reaffirms Hold Rating for GSK (LON:GSK)

GSK (LON:GSK)‘s stock had its “hold” rating reiterated by Deutsche Bank Aktiengesellschaft in a research note issued to investors on Tuesday, Digital Look reports. They presently have a GBX 2,000 target price on the stock. Deutsche Bank Aktiengesellschaft’s price objective suggests a potential upside of 10.53% from the company’s current price.

Other equities analysts have also issued reports about the stock. Berenberg Bank upped their price objective on shares of GSK from GBX 2,000 to GBX 2,200 and gave the stock a “hold” rating in a report on Tuesday, September 15th. Jefferies Financial Group reiterated a “buy” rating and issued a GBX 2,500 target price on shares of GSK in a report on Wednesday, July 29th. Finally, Royal Bank Of Canada reissued a “sector perform” rating and issued a GBX 1,975 target price on shares of GSK in a research report on Tuesday, September 8th. Two research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of GBX 2,064.38.

GSK Stock Down 1.2%

Shares of LON:GSK opened at GBX 1,809.50 on Tuesday. The company has a market capitalization of £72.51 billion, a price-to-earnings ratio of 15.36, a PEG ratio of 1.24 and a beta of 0.29. GSK has a 12-month low of GBX 1,592 and a 12-month high of GBX 2,282. The business has a 50-day moving average price of GBX 1,884.73 and a 200 day moving average price of GBX 1,943.77. The company has a current ratio of 0.82, a quick ratio of 0.73 and a debt-to-equity ratio of 103.36.

GSK (LON:GSK) last posted its earnings results on Tuesday, July 28th. The company reported GBX 10.80 EPS for the quarter. GSK had a net margin of 14.52% and a return on equity of 28.35%. Sell-side analysts expect that GSK will post 175.980975 EPS for the current year.

Insiders Place Their Bets

In related news, insider Anne Beal acquired 637 shares of GSK stock in a transaction dated Friday, September 18th. The shares were acquired at an average cost of GBX 4,985 per share, for a total transaction of £31,754.45. Also, insider Jonathan Symonds bought 1,500 shares of the firm’s stock in a transaction that occurred on Friday, September 18th. The stock was bought at an average price of GBX 1,881 per share, with a total value of £28,215. Insiders have bought 2,144 shares of company stock worth $6,009,566 in the last ninety days. Corporate insiders own 0.20% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.